enGene Holdings Inc. Warrants
enGene Holdings Inc. Warrants
Your view on ENGNW
Overview
What the company does, where it operates, and who runs it.
About enGene Holdings Inc. Warrants
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald H. W. Cooper
- Headquarters
- 4868 Rue Levy, Montreal, QC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald H. W. Cooper
- Headquarters
- 4868 Rue Levy, Montreal, QC, CA
EnGene Holdings Inc., through its enGene, Inc. subsidiary, is a clinical-stage biotechnology company dedicated to advancing genetic medicines. These innovative therapies are designed for targeted delivery to mucosal tissues and other bodily organs.
Its foremost developmental asset, EG-70 (detalimogene voraplasmid), represents a non-viral immunotherapy. This treatment is specifically aimed at patients with non-muscle invasive bladder cancer, specifically the carcinoma-in-situ (CIS) subtype, who have shown no response to Bacillus Calmette-Guérin (BCG) therapy.
Established in 2023, the firm's operations are based in Saint-Laurent, Canada.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for enGene Holdings Inc. Warrants from FRC's valuation model, read against the market price. ENGNW last traded at $0.27; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for enGene Holdings Inc. Warrants. Starting points for enGene Holdings Inc. Warrants: EPS -$0.07, beta -0.28 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for enGene Holdings Inc. Warrants. enGene Holdings Inc. Warrants does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for enGene Holdings Inc. Warrants. Trailing twelve-month EPS for enGene Holdings Inc. Warrants stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings Estimate
| EPS | Current QtrOct 2026 | Next QtrJan 2027 | Current YearFY Oct 2026 | Next YearFY Oct 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.46 | -$0.34 | -$1.81 | -$1.50 |
| Low estimate | -$0.46 | -$0.34 | -$1.81 | -$1.50 |
| High estimate | -$0.46 | -$0.34 | -$1.81 | -$1.50 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.74 | -$0.44 | -$2.29 | — |
| Growth | +37.4% | +23.3% | +20.8% | — |
Revenue Estimate
| Revenue | Current QtrOct 2026 | Next QtrJan 2027 | Current YearFY Oct 2026 | Next YearFY Oct 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $1.79M | $5.83M |
| Low estimate | $0.00 | $0.00 | $1.79M | $5.71M |
| High estimate | $0.00 | $0.00 | $1.79M | $5.95M |
| No. of analysts | 0 | 0 | 8 | 7 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for enGene Holdings Inc. Warrants. enGene Holdings Inc. Warrants has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
enGene Holdings Inc. Warrants valued side by side against its closest peers. enGene Holdings Inc. Warrants is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by enGene Holdings Inc. Warrants executives and directors. Shares of enGene Holdings Inc. Warrants have traded between $0.50 and $2.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for enGene Holdings Inc. Warrants. Coverage tracks enGene Holdings Inc. Warrants within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of enGene Holdings Inc. Warrants.